...So lots to cover. We were just talking, we only have 25 minutes. And with Exelixis, there's really a lot going on these days. So let's kind of dive right into, let's talk about commercial first. So Cabo had a very strong Q1, driven by several things. Number one, prescriptions continue to go up. It's obviously continuing to capture share in RCC. There was a $12 million clinical trial order, but for the audience, historically, that's range between $4 million and $22 million per quarter. In the last two years, it's kind of ranged between $4 million and $12 million. So it kind of fluctuates up and down a little bit. There was very little, you said, on the NET approval, the neuroendocrine tumors. It was only approved a week. There was a week left in the quarter. And the gross to net was mostly in line. So I guess the first question is IQVIA -- the trackers really didn't do a good job tracking this quarter. Usually, they do. I know there was usually a gross to net benefit or a Part D. The Part...
